Show simple item record

dc.contributor.authorWang, Men_GB
dc.contributor.authorRule, Sen_GB
dc.contributor.authorMartin, Pen_GB
dc.contributor.authorGoy, Aen_GB
dc.contributor.authorAuer, Ren_GB
dc.contributor.authorKahl, Ben_GB
dc.contributor.authorJurczak, Wen_GB
dc.contributor.authorAdvani, Ren_GB
dc.contributor.authorRomaguera, Jen_GB
dc.contributor.authorWilliams, Men_GB
dc.contributor.authorBarrientos, Jen_GB
dc.contributor.authorChmielowska, Een_GB
dc.contributor.authorRadford, John Aen_GB
dc.contributor.authorStilgenbauer, Sen_GB
dc.contributor.authorDreyling, Men_GB
dc.contributor.authorJedrzejczak, Wen_GB
dc.contributor.authorJohnson, Pen_GB
dc.contributor.authorSpurgeon, Sen_GB
dc.contributor.authorLi, Len_GB
dc.contributor.authorZhang, Len_GB
dc.contributor.authorNewberry, Ken_GB
dc.contributor.authorOu, Zen_GB
dc.contributor.authorCheng, Nen_GB
dc.contributor.authorFang, Ben_GB
dc.contributor.authorMcGreivy, Jen_GB
dc.contributor.authorClow, Fen_GB
dc.contributor.authorBuggy, Jen_GB
dc.contributor.authorChang, Ben_GB
dc.contributor.authorBeaupre, Den_GB
dc.contributor.authorKunkel, Len_GB
dc.contributor.authorBlum, Ken_GB
dc.date.accessioned2013-09-25T13:50:41Z
dc.date.available2013-09-25T13:50:41Z
dc.date.issued2013-08-08
dc.identifier.citationTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. 2013, 369 (6):507-16 N Engl J Meden_GB
dc.identifier.issn1533-4406
dc.identifier.pmid23782157
dc.identifier.doi10.1056/NEJMoa1306220
dc.identifier.urihttp://hdl.handle.net/10541/302282
dc.description.abstractBruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen_GB
dc.subject.meshAdministration, Oral
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLymphocyte Count
dc.subject.meshLymphoma, Mantle-Cell
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshProtein-Tyrosine Kinases
dc.subject.meshPyrazoles
dc.subject.meshPyrimidines
dc.subject.meshRecurrence
dc.subject.meshSurvival Analysis
dc.titleTargeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.en_GB
dc.identifier.journalNew England Journal of Medicineen_GB
html.description.abstractBruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.


This item appears in the following Collection(s)

Show simple item record